FABPulous B.V. a Maastricht-The Netherlands-based developer of a disposable device which allows for rapid semi-quantitative diagnostic testing in blood or plasma, has completed its first institutional round of financing.
The round was co-led by Thuja Capital, Health Innovation Fund, Limburg Ventures and NV Industriebank LIOF, with participation from existing shareholder MeDaVinci Development.
The new financing will enable the company to develop the device and launch its first application as a rapid in vitro diagnostic (IVD) test for myocardial infarction.
The company spun out of Maastricht University and was founded at the end of 2008 by BioMedbooster, with start-up capital provided by MeDaVinci Development.
Prof. Dr. Jan Glatz, who has built a track record in the field of cardiovascular research, was involved from the start and will continue to serve as the Chief Scientific Officer of FABPulous.
In conjunction with the financing, Michel Briejer will join the supervisory board of directors of FABPulous as Chairman, with other investors also represented by John Vossen (NV Industriebank LIOF), Marcel Kloosterman (Limburg Ventures) and Dick Sietses (Health Innovation Fund). Ger Biesbrouck (MeDaVinci Development) and Erik Wolters (BioMedbooster).